Literature DB >> 29602797

Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Hsia-Lien Lin1, Haoming Zhang1, Paul F Hollenberg2.   

Abstract

17α-Ethynylestradiol (EE), a major component of many oral contraceptives, affects the activities of a number of the human cytochrome P450 (P450) enzymes. Here, we characterized the effect of EE on CYP2J2, a major human P450 isoform that participates in metabolism of arachidonic acid. EE inactivated the hydroxyebastine carboxylation activity of CYP2J2 in a reconstituted system. The loss of activity is time and concentration dependent and requires NADPH. The KI and kinact values for the inactivation were 3.6 μM and 0.08 minute-1, respectively. Inactivation of CYP2J2 by EE was due to formation of a heme adduct as well as an apoprotein adduct. Mass spectral analysis of CYP2J2 partially inactivated by EE showed two distinct protein masses in the deconvoluted spectrum that exhibited a mass difference of approximately 312 Da, which is equivalent to the sum of the mass of EE and one oxygen atom. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis revealed a heme adduct with MH+ ion at m/z 875.5, corresponding to alkylation of an iron-depleted prosthetic heme by EE plus one oxygen atom. The reactive intermediate responsible for covalently modifying both the prosthetic heme and apoprotein was characterized by trapping with glutathione (GSH). LC-MS/MS analysis revealed two GSH conjugate isomers with MH+ ions at m/z 620, which were formed by reaction between GSH and EE with the oxygen being added to either the internal or terminal carbon of the ethynyl moiety. High-pressure liquid chromatography analysis revealed that three other major metabolites were formed during EE metabolism by CYP2J2.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29602797      PMCID: PMC5931439          DOI: 10.1124/dmd.118.080903

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  55 in total

1.  Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

Authors:  Takanori Hashizume; Susumu Imaoka; Masashi Mise; Yoshiaki Terauchi; Toshihiko Fujii; Hisashi Miyazaki; Tetsuya Kamataki; Yoshihiko Funae
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.

Authors:  Kwang-Hyeon Liu; Mi-Gyung Kim; Dong-Jun Lee; Yune-Jung Yoon; Min-Jung Kim; Ji-Hong Shon; Chang Soo Choi; Young Kil Choi; Zeuresenay Desta; Jae-Gook Shin
Journal:  Drug Metab Dispos       Date:  2006-08-08       Impact factor: 3.922

3.  Evidence of higher ethynylestradiol blood levels in human hypertensive oral contraceptive users.

Authors:  B S Ahluwalia; C L Curry; C L Crocker; P S Verma
Journal:  Fertil Steril       Date:  1977-06       Impact factor: 7.329

4.  No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.

Authors:  K Laine; G Tybring; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

Review 5.  Metabolism of 17 alpha-ethynylestradiol in humans.

Authors:  F P Guengerich
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

6.  Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists.

Authors:  Kasem Nithipatikom; Daniel M Brody; Alan T Tang; Vijaya L Manthati; John R Falck; Carol L Williams; William B Campbell
Journal:  Cancer Sci       Date:  2010-08-27       Impact factor: 6.716

Review 7.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Authors:  John M Seubert; Darryl C Zeldin; Kasem Nithipatikom; Garrett J Gross
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-07-10       Impact factor: 3.072

8.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

9.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

10.  Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.

Authors:  Sanna Palovaara; Olavi Pelkonen; Jouko Uusitalo; Stefan Lundgren; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

View more
  3 in total

Review 1.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

Review 2.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 3.  Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.

Authors:  F Peter Guengerich
Journal:  Biomol Ther (Seoul)       Date:  2022-01-01       Impact factor: 4.634

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.